首页 > 最新文献

International Journal of Nephrology and Renovascular Disease最新文献

英文 中文
One-year Survival of End-Stage Kidney Disease Patients Undergoing Hemodialysis in Indonesia. 印度尼西亚接受血液透析的终末期肾病患者的一年生存率
IF 2.1 Q2 UROLOGY & NEPHROLOGY Pub Date : 2025-03-12 eCollection Date: 2025-01-01 DOI: 10.2147/IJNRD.S508012
Rizky Andhika, Afiatin, Rudi Supriyadi, Ria Bandiara, Lilik Sukesi, Adhika Putra Sudarmadi, Kurnia Wahyudi, Yulia Sofiatin

Background: Chronic Kidney Disease (CKD) represents a significant global health challenge, with Indonesia experiencing the highest surge in End-Stage Kidney Disease (ESKD) prevalence over the past decade. Kidney registries are essential for reporting health outcomes, evaluating healthcare services, advocating for policy change, and informing health infrastructure development. Survival rates in ESKD patients undergoing hemodialysis (HD) are a critical outcome measure. However, there is a lack of survival analysis data for ESKD patients receiving HD in Indonesia.

Objective: This study aims to assess the one-year survival rate of ESKD patients undergoing HD in Indonesia, while examining risk factors associated with survival, including age, gender, CKD etiology, and dialysis adequacy.

Methods: This analytical observational study employed a retrospective cohort design, utilizing patient data from Indonesia Renal Registry between 2016 and 2019. Kaplan-Meier survival curves were generated, and Log rank test was applied to assess the significance of survival differences across subgroups based on age, gender, CKD etiology, and dialysis adequacy.

Results: A total of 122,449 ESKD patients on HD were analyzed, with a mean age of 52 years; majority (55.5%) were male, and hypertensive kidney disease was the leading cause of CKD (43.7%). The overall one-year survival rate was 91.5% (95% CI: 91.3-91.6). Survival decreased significantly with advancing age (p < 0.01), and female patients exhibited lower survival rates compared to males (p < 0.01). Patients with diabetic nephropathy had the lowest survival rate among CKD etiologies (p < 0.01). Dialysis adequacy, assessed in 11,633 patients, revealed that 69.2% had a Kt/V below 1.8. Those with inadequate dialysis had significantly lower survival rates (p=0.00015).

Conclusion: The one-year survival rate for ESKD patients undergoing HD in Indonesia is 91.5%. Increased age, female, diabetic nephropathy as the underlying CKD etiology, and inadequate dialysis adequacy are associated with reduced survival rates.

背景:慢性肾脏疾病(CKD)是一项重大的全球健康挑战,印度尼西亚在过去十年中经历了终末期肾脏疾病(ESKD)患病率的最高激增。肾脏登记对于报告健康结果、评估卫生保健服务、倡导政策变化和告知卫生基础设施发展至关重要。接受血液透析(HD)的ESKD患者的生存率是一项关键的预后指标。然而,缺乏印度尼西亚接受HD的ESKD患者的生存分析数据。目的:本研究旨在评估印度尼西亚接受HD的ESKD患者的一年生存率,同时检查与生存相关的危险因素,包括年龄、性别、CKD病因和透析充分性。方法:本分析性观察性研究采用回顾性队列设计,利用2016年至2019年印度尼西亚肾脏登记处的患者数据。生成Kaplan-Meier生存曲线,并应用Log rank检验评估基于年龄、性别、CKD病因和透析充分性的亚组间生存差异的显著性。结果:共分析了122,449例患有HD的ESKD患者,平均年龄为52岁;男性居多(55.5%),高血压肾病是CKD的主要原因(43.7%)。总1年生存率为91.5% (95% CI: 91.3-91.6)。随着年龄的增长,患者的生存率明显降低(p < 0.01),女性患者的生存率低于男性患者(p < 0.01)。糖尿病肾病患者在CKD病因中生存率最低(p < 0.01)。11,633例患者的透析充分性评估显示,69.2%的患者Kt/V低于1.8。透析不充分的患者生存率明显较低(p=0.00015)。结论:印度尼西亚ESKD患者接受HD的1年生存率为91.5%。年龄增加、女性、糖尿病肾病作为CKD的潜在病因、透析不足与生存率降低相关。
{"title":"One-year Survival of End-Stage Kidney Disease Patients Undergoing Hemodialysis in Indonesia.","authors":"Rizky Andhika, Afiatin, Rudi Supriyadi, Ria Bandiara, Lilik Sukesi, Adhika Putra Sudarmadi, Kurnia Wahyudi, Yulia Sofiatin","doi":"10.2147/IJNRD.S508012","DOIUrl":"https://doi.org/10.2147/IJNRD.S508012","url":null,"abstract":"<p><strong>Background: </strong>Chronic Kidney Disease (CKD) represents a significant global health challenge, with Indonesia experiencing the highest surge in End-Stage Kidney Disease (ESKD) prevalence over the past decade. Kidney registries are essential for reporting health outcomes, evaluating healthcare services, advocating for policy change, and informing health infrastructure development. Survival rates in ESKD patients undergoing hemodialysis (HD) are a critical outcome measure. However, there is a lack of survival analysis data for ESKD patients receiving HD in Indonesia.</p><p><strong>Objective: </strong>This study aims to assess the one-year survival rate of ESKD patients undergoing HD in Indonesia, while examining risk factors associated with survival, including age, gender, CKD etiology, and dialysis adequacy.</p><p><strong>Methods: </strong>This analytical observational study employed a retrospective cohort design, utilizing patient data from Indonesia Renal Registry between 2016 and 2019. Kaplan-Meier survival curves were generated, and Log rank test was applied to assess the significance of survival differences across subgroups based on age, gender, CKD etiology, and dialysis adequacy.</p><p><strong>Results: </strong>A total of 122,449 ESKD patients on HD were analyzed, with a mean age of 52 years; majority (55.5%) were male, and hypertensive kidney disease was the leading cause of CKD (43.7%). The overall one-year survival rate was 91.5% (95% CI: 91.3-91.6). Survival decreased significantly with advancing age (p < 0.01), and female patients exhibited lower survival rates compared to males (p < 0.01). Patients with diabetic nephropathy had the lowest survival rate among CKD etiologies (p < 0.01). Dialysis adequacy, assessed in 11,633 patients, revealed that 69.2% had a Kt/V below 1.8. Those with inadequate dialysis had significantly lower survival rates (p=0.00015).</p><p><strong>Conclusion: </strong>The one-year survival rate for ESKD patients undergoing HD in Indonesia is 91.5%. Increased age, female, diabetic nephropathy as the underlying CKD etiology, and inadequate dialysis adequacy are associated with reduced survival rates.</p>","PeriodicalId":14181,"journal":{"name":"International Journal of Nephrology and Renovascular Disease","volume":"18 ","pages":"87-101"},"PeriodicalIF":2.1,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11910932/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Causal Relationship Between Intelligence, Noncognitive Education, Cognition and Urinary Tract or Kidney Infection: A Mendelian Randomization Study. 智力、非认知教育、认知与尿路或肾脏感染的因果关系:一项孟德尔随机研究。
IF 2.1 Q2 UROLOGY & NEPHROLOGY Pub Date : 2025-03-07 eCollection Date: 2025-01-01 DOI: 10.2147/IJNRD.S511736
Shuai Fu, Qiang Li, Li Cheng, Sheng Wan, Quan Wang, Yonglong Min, Yanghao Xie, Huizhen Liu, Taotao Hu, Hong Liu, Weidong Chen, Yanmin Zhang, Fei Xiong

Background: The occurrence of urinary tract or kidney infection is correlated with intelligence, noncognitive education and cognition, but the causal relationship between them remains uncertain, and which risk factors mediate this causal relationship remains unknown.

Methods: The intelligence (n=269,867), noncognitive education (n=510,795) and cognition data (n=257,700) were obtained from genome-wide association studies (GWAS) conducted in individuals of European ethnicities. The genetic associations between these factors and urinary tract or kidney infection (UK Biobank, n=397,867) were analyzed using linkage disequilibrium score regression. We employed a two-sample univariate and multivariate Mendelian randomization to evaluate the causal relationship, and utilized a two-step Mendelian randomization to examine the involvement of 28 potential mediators and their respective mediating proportions.

Results: The genetic correlation coefficients of intelligence, noncognitive education, cognition, and urinary tract or kidney infection were -0.338, -0.218, and -0.330. The Mendelian randomization using the inverse variance weighted method revealed each 1-SD increase in intelligence, the risk of infection decreased by 15.9%, while after adjusting for noncognitive education, the risk decreased by 20%. For each 1-SD increase in noncognitive education, the risk of infection decreased by 8%, which further reduced to 7.1% after adjusting for intelligence and to 6.7% after adjusting for cognition. For each 1-SD increase in cognition, the risk of infection decreased by 10.8%, increasing to 11.9% after adjusting for noncognitive education. The effects of intelligence and cognition are interdependent. 2 out of 28 potential mediating factors exhibited significant mediation effects in the causal relationship between noncognitive education and urinary tract or kidney infection, with body mass index accounting for 12.1% of the mediation effect and smoking initiation accounting for 14.7%.

Conclusion: Enhancing intelligence, noncognitive education, and cognition can mitigate the susceptibility to urinary tract or kidney infection. Noncognitive education exhibited independent effect, while body mass index and smoking initiation assuming a mediating role.

背景:尿路或肾脏感染的发生与智力、非认知教育和认知相关,但两者之间的因果关系尚不确定,哪些危险因素介导了这种因果关系尚不清楚。方法:从欧洲民族个体的全基因组关联研究(GWAS)中获得智力(n=269,867)、非认知教育(n=510,795)和认知数据(n=257,700)。使用连锁不平衡评分回归分析这些因素与尿路或肾脏感染之间的遗传关联(UK Biobank, n=397,867)。我们采用双样本单变量和多变量孟德尔随机化来评估因果关系,并利用两步孟德尔随机化来检查28个潜在中介因素的参与及其各自的中介比例。结果:智力、非认知教育、认知与尿路或肾脏感染的遗传相关系数分别为-0.338、-0.218和-0.330。采用反方差加权方法的孟德尔随机化显示,智力每增加1个标准差,感染风险降低15.9%,而在调整非认知教育后,感染风险降低20%。非认知教育每增加1个sd,感染风险降低8%,在调整智力后进一步降低到7.1%,在调整认知后进一步降低到6.7%。认知水平每提高1-SD,感染风险降低10.8%,经非认知教育调整后,感染风险增加至11.9%。智力和认知的影响是相互依存的。28个潜在中介因素中有2个在非认知教育与尿路或肾脏感染的因果关系中表现出显著的中介作用,其中体重指数占中介效应的12.1%,吸烟开始占中介效应的14.7%。结论:提高智力、非认知教育和认知能减轻尿路或肾脏感染的易感性。非认知教育表现出独立的影响,而体重指数和吸烟开始起中介作用。
{"title":"Causal Relationship Between Intelligence, Noncognitive Education, Cognition and Urinary Tract or Kidney Infection: A Mendelian Randomization Study.","authors":"Shuai Fu, Qiang Li, Li Cheng, Sheng Wan, Quan Wang, Yonglong Min, Yanghao Xie, Huizhen Liu, Taotao Hu, Hong Liu, Weidong Chen, Yanmin Zhang, Fei Xiong","doi":"10.2147/IJNRD.S511736","DOIUrl":"10.2147/IJNRD.S511736","url":null,"abstract":"<p><strong>Background: </strong>The occurrence of urinary tract or kidney infection is correlated with intelligence, noncognitive education and cognition, but the causal relationship between them remains uncertain, and which risk factors mediate this causal relationship remains unknown.</p><p><strong>Methods: </strong>The intelligence (n=269,867), noncognitive education (n=510,795) and cognition data (n=257,700) were obtained from genome-wide association studies (GWAS) conducted in individuals of European ethnicities. The genetic associations between these factors and urinary tract or kidney infection (UK Biobank, n=397,867) were analyzed using linkage disequilibrium score regression. We employed a two-sample univariate and multivariate Mendelian randomization to evaluate the causal relationship, and utilized a two-step Mendelian randomization to examine the involvement of 28 potential mediators and their respective mediating proportions.</p><p><strong>Results: </strong>The genetic correlation coefficients of intelligence, noncognitive education, cognition, and urinary tract or kidney infection were -0.338, -0.218, and -0.330. The Mendelian randomization using the inverse variance weighted method revealed each 1-SD increase in intelligence, the risk of infection decreased by 15.9%, while after adjusting for noncognitive education, the risk decreased by 20%. For each 1-SD increase in noncognitive education, the risk of infection decreased by 8%, which further reduced to 7.1% after adjusting for intelligence and to 6.7% after adjusting for cognition. For each 1-SD increase in cognition, the risk of infection decreased by 10.8%, increasing to 11.9% after adjusting for noncognitive education. The effects of intelligence and cognition are interdependent. 2 out of 28 potential mediating factors exhibited significant mediation effects in the causal relationship between noncognitive education and urinary tract or kidney infection, with body mass index accounting for 12.1% of the mediation effect and smoking initiation accounting for 14.7%.</p><p><strong>Conclusion: </strong>Enhancing intelligence, noncognitive education, and cognition can mitigate the susceptibility to urinary tract or kidney infection. Noncognitive education exhibited independent effect, while body mass index and smoking initiation assuming a mediating role.</p>","PeriodicalId":14181,"journal":{"name":"International Journal of Nephrology and Renovascular Disease","volume":"18 ","pages":"71-85"},"PeriodicalIF":2.1,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11895678/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of Potentially Nephrotoxic Drug Prescriptions in Chronic Kidney Disease Outpatients at a Hospital in Indonesia. 印度尼西亚某医院慢性肾病门诊患者潜在肾毒性药物处方评估
IF 2.1 Q2 UROLOGY & NEPHROLOGY Pub Date : 2025-02-26 eCollection Date: 2025-01-01 DOI: 10.2147/IJNRD.S503573
Larasati Arrum Kusumawardani, Hindun Wilda Risni, Darisa Naurahhanan, Syed Azhar Syed Sulaiman

Background: Nephrotoxic drugs can worsen the kidney function of patients with chronic kidney disease (CKD). There is still a limited amount of research investigating nephrotoxic drugs in Indonesia. This study aims to analyze the prevalence of potentially nephrotoxic drugs (PND) prescriptions and the association of patients' characteristics with PND prescribing.

Methods: This cross-sectional study employed retrospective data from Universitas Indonesia Hospital (RSUI), focusing on CKD outpatients treated between January 2019 and December 2022. CKD patients over the age of 18 were included, with exclusions for those suspected of having CKD, those with a history of kidney transplants, or missing critical data. The study outcome was the prevalence of patients prescribed PND, determined using reliable references to assess potential nephrotoxicity. Furthermore, compliance with clinical guidelines was evaluated at the individual drug level, with each PND within a prescription treated as a separate case. Descriptive analyses were carried out to determine prevalence, which were presented as percentages. Logistic regression analysis was performed to examine the association between patient characteristics and the prescription of PND.

Results: In total, 248 patients were evaluated. The findings revealed that 177 out of 248 patients (71.4%) were prescribed at least one PND. The categories of these drugs included antihypertensives (50.9%), antigout medications (17.8%), antiplatelets (10.5%), antibiotics (9.8%), NSAIDs (5.8%), and antiulcer agents (5.2%). Of 275 cases of PND prescriptions, 220 (80.0%) complied to treatment guidelines, while 55 (20.0%) did not. Logistic regression analysis indicated that patients taking more than four additional medications were more likely to be prescribed PNDs than those on fewer medications (aOR 2.454, 95% CI 1.399-4.305).

Conclusion: Although non-compliance cases are relatively low, PNDs are frequently prescribed to CKD patients, with the risk rising as the number of comedications increases. Measures are needed to ensure guideline compliance, including accurate dosage assessments and outcome monitoring.

背景:肾毒性药物可使慢性肾病(CKD)患者的肾功能恶化。在印度尼西亚,关于肾毒性药物的研究仍然有限。本研究旨在分析潜在肾毒性药物(PND)处方的流行情况以及患者特征与PND处方的关系。方法:本横断面研究采用印度尼西亚大学医院(RSUI)的回顾性数据,重点关注2019年1月至2022年12月期间接受CKD门诊治疗的患者。年龄在18岁以上的CKD患者被纳入研究,排除了那些怀疑患有CKD、有肾移植史或缺少关键数据的患者。研究结果是使用可靠的参考资料来评估潜在的肾毒性,确定处方PND患者的患病率。此外,在单个药物水平上评估临床指南的依从性,将处方中的每个PND视为单独的病例。进行描述性分析以确定患病率,以百分比表示。采用Logistic回归分析检验患者特征与PND处方之间的关系。结果:共评估248例患者。研究结果显示,248名患者中有177名(71.4%)至少开了一种PND。这些药物的类别包括抗高血压药(50.9%)、抗痛风药(17.8%)、抗血小板药(10.5%)、抗生素(9.8%)、非甾体抗炎药(5.8%)和抗溃疡药(5.2%)。在275例PND处方中,220例(80.0%)遵守治疗指南,55例(20.0%)未遵守治疗指南。Logistic回归分析显示,服用4种以上额外药物的患者比服用较少药物的患者更容易被处方pnd (aOR 2.454, 95% CI 1.399-4.305)。结论:虽然不遵医嘱的病例相对较少,但慢性肾病患者经常使用pnd,而且随着用药次数的增加,风险也在增加。需要采取措施确保指南的遵守,包括准确的剂量评估和结果监测。
{"title":"Assessment of Potentially Nephrotoxic Drug Prescriptions in Chronic Kidney Disease Outpatients at a Hospital in Indonesia.","authors":"Larasati Arrum Kusumawardani, Hindun Wilda Risni, Darisa Naurahhanan, Syed Azhar Syed Sulaiman","doi":"10.2147/IJNRD.S503573","DOIUrl":"https://doi.org/10.2147/IJNRD.S503573","url":null,"abstract":"<p><strong>Background: </strong>Nephrotoxic drugs can worsen the kidney function of patients with chronic kidney disease (CKD). There is still a limited amount of research investigating nephrotoxic drugs in Indonesia. This study aims to analyze the prevalence of potentially nephrotoxic drugs (PND) prescriptions and the association of patients' characteristics with PND prescribing.</p><p><strong>Methods: </strong>This cross-sectional study employed retrospective data from Universitas Indonesia Hospital (RSUI), focusing on CKD outpatients treated between January 2019 and December 2022. CKD patients over the age of 18 were included, with exclusions for those suspected of having CKD, those with a history of kidney transplants, or missing critical data. The study outcome was the prevalence of patients prescribed PND, determined using reliable references to assess potential nephrotoxicity. Furthermore, compliance with clinical guidelines was evaluated at the individual drug level, with each PND within a prescription treated as a separate case. Descriptive analyses were carried out to determine prevalence, which were presented as percentages. Logistic regression analysis was performed to examine the association between patient characteristics and the prescription of PND.</p><p><strong>Results: </strong>In total, 248 patients were evaluated. The findings revealed that 177 out of 248 patients (71.4%) were prescribed at least one PND. The categories of these drugs included antihypertensives (50.9%), antigout medications (17.8%), antiplatelets (10.5%), antibiotics (9.8%), NSAIDs (5.8%), and antiulcer agents (5.2%). Of 275 cases of PND prescriptions, 220 (80.0%) complied to treatment guidelines, while 55 (20.0%) did not. Logistic regression analysis indicated that patients taking more than four additional medications were more likely to be prescribed PNDs than those on fewer medications (aOR 2.454, 95% CI 1.399-4.305).</p><p><strong>Conclusion: </strong>Although non-compliance cases are relatively low, PNDs are frequently prescribed to CKD patients, with the risk rising as the number of comedications increases. Measures are needed to ensure guideline compliance, including accurate dosage assessments and outcome monitoring.</p>","PeriodicalId":14181,"journal":{"name":"International Journal of Nephrology and Renovascular Disease","volume":"18 ","pages":"59-69"},"PeriodicalIF":2.1,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11872086/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143541945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MicroRNA-203 Expression as Potential Biomarker for Lupus Nephritis. MicroRNA-203表达作为狼疮肾炎的潜在生物标志物。
IF 2.1 Q2 UROLOGY & NEPHROLOGY Pub Date : 2025-02-17 eCollection Date: 2025-01-01 DOI: 10.2147/IJNRD.S485409
Yuswanto Setyawan, Hani Susianti, Hermin Sulistyarti, Matthew Brian Khrisna, Dearikha Karina Mayashinta, Loeki Enggar Fitri, Nur Samsu

Introduction and purpose: Lupus nephritis (LN) is the main cause of morbidity and mortality in systemic lupus erythematosus (SLE) patients, therefore the discovery of new biomarkers, which are reliable for the diagnosis of NL is necessary. Various studies have reported alteration of some miRNAs expression in LN, that considered as biomarkers and/or therapeutic targets in LN. MicroRNA-203 has been associated with the development of nephritis in SLE patients, playing an important role in the initiation and progression of the disease, but research on circulating miRNA-203 expression in LN in clinical practice is still very limited. The aim of this study was to prove the role of microRNA-203 in LN.

Patients and methods: Serum was obtained from 40 participants consisting of 20 SLE patients and 20 LN patients. The diagnostic of SLE and LN was based on the ACR 1997 criteria. MicroRNA-203 expression was determined by real-time Polymerase Chain Reaction (PCR). Statistical analysis was performed with Mann-Whitney test.

Results: The expression of miRNA-203 in the SLE group was 1.66 (0.00-8.64) and in the NL group was 5.18 (0.25-49.84). There were significant differences in microRNA-203 expression between SLE and LN patients (p=0.003).

Conclusion: MicroRNA-203 expression might be associated with nephritis manifestations in SLE patients.

简介及目的:狼疮肾炎(Lupus nephroritis, LN)是系统性红斑狼疮(systemic Lupus erythematosus, SLE)患者发病和死亡的主要原因,因此有必要发现新的、可靠的生物标志物来诊断狼疮肾炎。各种研究报道了LN中一些mirna表达的改变,这些mirna被认为是LN的生物标志物和/或治疗靶点。MicroRNA-203与SLE患者肾炎的发生发展相关,在疾病的发生和发展中起着重要作用,但在临床实践中对LN中循环miRNA-203表达的研究仍然非常有限。本研究的目的是为了证明microRNA-203在LN中的作用。患者和方法:从40名参与者中获得血清,其中包括20名SLE患者和20名LN患者。SLE和LN的诊断基于ACR 1997标准。实时聚合酶链反应(real-time Polymerase Chain Reaction, PCR)检测MicroRNA-203的表达。采用Mann-Whitney检验进行统计学分析。结果:miRNA-203在SLE组的表达为1.66(0.00 ~ 8.64),在NL组的表达为5.18(0.25 ~ 49.84)。SLE与LN患者microRNA-203表达差异有统计学意义(p=0.003)。结论:MicroRNA-203的表达可能与SLE患者肾炎的表现有关。
{"title":"MicroRNA-203 Expression as Potential Biomarker for Lupus Nephritis.","authors":"Yuswanto Setyawan, Hani Susianti, Hermin Sulistyarti, Matthew Brian Khrisna, Dearikha Karina Mayashinta, Loeki Enggar Fitri, Nur Samsu","doi":"10.2147/IJNRD.S485409","DOIUrl":"10.2147/IJNRD.S485409","url":null,"abstract":"<p><strong>Introduction and purpose: </strong>Lupus nephritis (LN) is the main cause of morbidity and mortality in systemic lupus erythematosus (SLE) patients, therefore the discovery of new biomarkers, which are reliable for the diagnosis of NL is necessary. Various studies have reported alteration of some miRNAs expression in LN, that considered as biomarkers and/or therapeutic targets in LN. MicroRNA-203 has been associated with the development of nephritis in SLE patients, playing an important role in the initiation and progression of the disease, but research on circulating miRNA-203 expression in LN in clinical practice is still very limited. The aim of this study was to prove the role of microRNA-203 in LN.</p><p><strong>Patients and methods: </strong>Serum was obtained from 40 participants consisting of 20 SLE patients and 20 LN patients. The diagnostic of SLE and LN was based on the ACR 1997 criteria. MicroRNA-203 expression was determined by real-time Polymerase Chain Reaction (PCR). Statistical analysis was performed with Mann-Whitney test.</p><p><strong>Results: </strong>The expression of miRNA-203 in the SLE group was 1.66 (0.00-8.64) and in the NL group was 5.18 (0.25-49.84). There were significant differences in microRNA-203 expression between SLE and LN patients (p=0.003).</p><p><strong>Conclusion: </strong>MicroRNA-203 expression might be associated with nephritis manifestations in SLE patients.</p>","PeriodicalId":14181,"journal":{"name":"International Journal of Nephrology and Renovascular Disease","volume":"18 ","pages":"53-58"},"PeriodicalIF":2.1,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11844303/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143483099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment Inertia and Symptom Burden in Anemia of CKD: Insights from the SATISFY Survey in the Middle East, South Africa, and Türkiye. 慢性肾病贫血的治疗惰性和症状负担:来自中东、南非和土耳其的调查。
IF 2.1 Q2 UROLOGY & NEPHROLOGY Pub Date : 2025-01-22 eCollection Date: 2025-01-01 DOI: 10.2147/IJNRD.S474716
Mustafa Arici, Saeed M G Al-Ghamdi, Alain G Assounga, Ahmed F El-Koraie, Abigail McMillan, Lucinda J Camidge, Budiwan Sumarsono, Martin Blogg, Daniel Bin Ng, Elvira P Lansang

Introduction: Limited data exist regarding treatment patterns and symptom burden of patients with anemia of chronic kidney disease (CKD) in the Middle East, South Africa, and Türkiye.

Methods: This real-world study explored clinical characteristics, symptom burden, and treatment patterns of patients with anemia of CKD living in the Middle East, South Africa, and Türkiye. Physician and patient perceptions of treatment were captured via cross-sectional surveys; patients' clinical characteristics were recorded by retrospective review of medical records.

Results: Data were collected from 1788 patients and 217 physicians. A high proportion of patients had never received treatment for their anemia (n = 701, 39.2%); the most common treatment was erythropoietin-stimulating agents (ESAs) + intravenous iron (n = 457, 50.3%). High symptom burden was reported, with lack of energy being the most common symptom (n = 394, 75.6% treated and n = 133, 59.9% non-treated patients). Patients' self-reported symptom burden was higher than physician-reported burden; less agreement was seen for non-dialysis-dependent (NDD) patients (kappa = 0.193, standard deviation [SD]: 0.081) than dialysis-dependent (DD) patients (kappa = 0.442, SD: 0.103). Median hemoglobin thresholds that physicians reported using for initiating treatment (NDD: <10.5 [interquartile range, 9.5-12.0] g/dL; DD: <9.3 [9.0-10.0] g/dL) were higher than actual test levels at treatment initiation (NDD: 9.2 [8.7-10.0] g/dL; DD: 9.0 [8.1-10.0] g/dL).

Conclusion: Treatment inertia is apparent despite high symptom burden in the Middle East, South Africa, and Türkiye, and disagreement was seen in physician and patient perspectives on symptomology. Improved awareness of this disagreement may help facilitate physician-patient dialogue to improve patient experience.

在中东、南非和土耳其,关于慢性肾脏疾病(CKD)贫血患者的治疗模式和症状负担的数据有限。方法:这项现实世界的研究探讨了生活在中东、南非和土耳其的CKD贫血患者的临床特征、症状负担和治疗模式。通过横断面调查捕获了医生和患者对治疗的看法;通过回顾性查阅病历记录患者的临床特征。结果:共收集患者1788例,医生217例。较高比例的患者从未接受过贫血治疗(n = 701, 39.2%);最常见的治疗是促红细胞生成素(ESAs) +静脉注射铁(n = 457, 50.3%)。据报道,症状负担高,精力不足是最常见的症状(n = 394,接受治疗的75.6%,n = 133,未接受治疗的59.9%)。患者自我报告的症状负担高于医生报告的负担;非透析依赖(NDD)患者(kappa = 0.193,标准差[SD]: 0.081)的一致性低于透析依赖(DD)患者(kappa = 0.442, SD: 0.103)。结论:尽管中东、南非和土耳其的症状负担很高,但治疗惯性是明显的,医生和患者对症状的看法存在分歧。提高对这种分歧的认识可能有助于促进医患对话,以改善患者体验。
{"title":"Treatment Inertia and Symptom Burden in Anemia of CKD: Insights from the SATISFY Survey in the Middle East, South Africa, and Türkiye.","authors":"Mustafa Arici, Saeed M G Al-Ghamdi, Alain G Assounga, Ahmed F El-Koraie, Abigail McMillan, Lucinda J Camidge, Budiwan Sumarsono, Martin Blogg, Daniel Bin Ng, Elvira P Lansang","doi":"10.2147/IJNRD.S474716","DOIUrl":"10.2147/IJNRD.S474716","url":null,"abstract":"<p><strong>Introduction: </strong>Limited data exist regarding treatment patterns and symptom burden of patients with anemia of chronic kidney disease (CKD) in the Middle East, South Africa, and Türkiye.</p><p><strong>Methods: </strong>This real-world study explored clinical characteristics, symptom burden, and treatment patterns of patients with anemia of CKD living in the Middle East, South Africa, and Türkiye. Physician and patient perceptions of treatment were captured via cross-sectional surveys; patients' clinical characteristics were recorded by retrospective review of medical records.</p><p><strong>Results: </strong>Data were collected from 1788 patients and 217 physicians. A high proportion of patients had never received treatment for their anemia (n = 701, 39.2%); the most common treatment was erythropoietin-stimulating agents (ESAs) + intravenous iron (n = 457, 50.3%). High symptom burden was reported, with lack of energy being the most common symptom (n = 394, 75.6% treated and n = 133, 59.9% non-treated patients). Patients' self-reported symptom burden was higher than physician-reported burden; less agreement was seen for non-dialysis-dependent (NDD) patients (kappa = 0.193, standard deviation [SD]: 0.081) than dialysis-dependent (DD) patients (kappa = 0.442, SD: 0.103). Median hemoglobin thresholds that physicians reported using for initiating treatment (NDD: <10.5 [interquartile range, 9.5-12.0] g/dL; DD: <9.3 [9.0-10.0] g/dL) were higher than actual test levels at treatment initiation (NDD: 9.2 [8.7-10.0] g/dL; DD: 9.0 [8.1-10.0] g/dL).</p><p><strong>Conclusion: </strong>Treatment inertia is apparent despite high symptom burden in the Middle East, South Africa, and Türkiye, and disagreement was seen in physician and patient perspectives on symptomology. Improved awareness of this disagreement may help facilitate physician-patient dialogue to improve patient experience.</p>","PeriodicalId":14181,"journal":{"name":"International Journal of Nephrology and Renovascular Disease","volume":"18 ","pages":"27-42"},"PeriodicalIF":2.1,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11766225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correlation Between the Inferior Vena Cava/Aorta (Ivc/Ao) Ratio and Serum Lactate Levels in Children With Renal Disorder. 肾病患儿下腔静脉/主动脉(Ivc/Ao)比值与血清乳酸水平的相关性
IF 2.1 Q2 UROLOGY & NEPHROLOGY Pub Date : 2025-01-22 eCollection Date: 2025-01-01 DOI: 10.2147/IJNRD.S488639
Dzulfikar Djalil Lukmanul Hakim, Ahmedz Widiasta, Dedi Rachmadi, Sri Endah Rahayunigsih, Putria Rayani Apandi, Riyadi Adrizain, Muhamad Rinaldhi Akbar Martiano

Background: Acute kidney injury (AKI) is common in critically ill children in the PICU, with incidence rates from 2.5% to 58%, impacting mortality and hospital duration. Early AKI detection is vital, but conventional hemodynamic monitoring often lacks specificity. This study investigates the relationship between the inferior vena cava/aortic (IVC/Ao) ratio and serum lactate levels as non-invasive indicators of renal hemodynamics and tissue perfusion in children. Understanding these parameters could improve early diagnosis, aid clinical decisions, and enhance outcomes for pediatric AKI patients, offering an accessible monitoring method for clinicians.

Methods: This cross-sectional study involved 48 pediatric patients aged 5-18 years showing Pediatric Early Warning Score (PEWS) ≥3 and diagnosed with renal disorders. Patients were admitted to the emergency department, high care unit, PICU, and pediatric ward at Dr. Hasan Sadikin Hospital, Bandung, between May and August 2023. AKI was diagnosed using pRIFLE or KDIGO criteria. The IVC/Ao ratio was assessed via transabdominal USG, and serum lactate levels were measured. Spearman correlation analysis was conducted to assess their relationship.

Results: The median (IQR) IVC/Ao ratio was 0.91 (0.70-1.10), and serum lactate levels were 1.5 (1.1-2.4) mmol/L. Spearman correlation analysis revealed a negative correlation between the IVC/Ao ratio and serum lactate (rho = -0.65, p < 0.001).

Conclusion: A decrease in the IVC/Ao ratio correlates with an increase in serum lactate levels in children with AKI.

背景:急性肾损伤(AKI)在重症儿童PICU中很常见,发生率为2.5% ~ 58%,影响死亡率和住院时间。早期AKI检测是至关重要的,但传统的血流动力学监测往往缺乏特异性。本研究探讨下腔静脉/主动脉(IVC/Ao)比值与血清乳酸水平作为儿童肾脏血流动力学和组织灌注的无创指标的关系。了解这些参数可以改善早期诊断,帮助临床决策,提高儿科AKI患者的预后,为临床医生提供一种方便的监测方法。方法:本横断面研究纳入48例5-18岁儿科早期预警评分(PEWS)≥3且诊断为肾脏疾病的儿童患者。患者于2023年5月至8月期间入住万隆哈桑·萨迪金医生医院的急诊科、高级监护病房、重症监护病房和儿科病房。AKI的诊断采用prile或KDIGO标准。经腹超声心动图评估IVC/Ao比值,测定血清乳酸水平。采用Spearman相关分析评价两者的关系。结果:中位IVC/Ao比值(IQR)为0.91(0.70 ~ 1.10),血清乳酸水平为1.5 (1.1 ~ 2.4)mmol/L。Spearman相关分析显示IVC/Ao比值与血清乳酸呈负相关(rho = -0.65, p < 0.001)。结论:AKI患儿IVC/Ao比值降低与血清乳酸水平升高相关。
{"title":"Correlation Between the Inferior Vena Cava/Aorta (Ivc/Ao) Ratio and Serum Lactate Levels in Children With Renal Disorder.","authors":"Dzulfikar Djalil Lukmanul Hakim, Ahmedz Widiasta, Dedi Rachmadi, Sri Endah Rahayunigsih, Putria Rayani Apandi, Riyadi Adrizain, Muhamad Rinaldhi Akbar Martiano","doi":"10.2147/IJNRD.S488639","DOIUrl":"10.2147/IJNRD.S488639","url":null,"abstract":"<p><strong>Background: </strong>Acute kidney injury (AKI) is common in critically ill children in the PICU, with incidence rates from 2.5% to 58%, impacting mortality and hospital duration. Early AKI detection is vital, but conventional hemodynamic monitoring often lacks specificity. This study investigates the relationship between the inferior vena cava/aortic (IVC/Ao) ratio and serum lactate levels as non-invasive indicators of renal hemodynamics and tissue perfusion in children. Understanding these parameters could improve early diagnosis, aid clinical decisions, and enhance outcomes for pediatric AKI patients, offering an accessible monitoring method for clinicians.</p><p><strong>Methods: </strong>This cross-sectional study involved 48 pediatric patients aged 5-18 years showing Pediatric Early Warning Score (PEWS) ≥3 and diagnosed with renal disorders. Patients were admitted to the emergency department, high care unit, PICU, and pediatric ward at Dr. Hasan Sadikin Hospital, Bandung, between May and August 2023. AKI was diagnosed using pRIFLE or KDIGO criteria. The IVC/Ao ratio was assessed via transabdominal USG, and serum lactate levels were measured. Spearman correlation analysis was conducted to assess their relationship.</p><p><strong>Results: </strong>The median (IQR) IVC/Ao ratio was 0.91 (0.70-1.10), and serum lactate levels were 1.5 (1.1-2.4) mmol/L. Spearman correlation analysis revealed a negative correlation between the IVC/Ao ratio and serum lactate (rho = -0.65, p < 0.001).</p><p><strong>Conclusion: </strong>A decrease in the IVC/Ao ratio correlates with an increase in serum lactate levels in children with AKI.</p>","PeriodicalId":14181,"journal":{"name":"International Journal of Nephrology and Renovascular Disease","volume":"18 ","pages":"43-51"},"PeriodicalIF":2.1,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11766292/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Financial Toxicity and Kidney Disease in Children and Adults: A Scoping Review. 儿童和成人的金融毒性与肾脏疾病:范围综述。
IF 2.1 Q2 UROLOGY & NEPHROLOGY Pub Date : 2025-01-21 eCollection Date: 2025-01-01 DOI: 10.2147/IJNRD.S485111
Rossella Siligato, Guido Gembillo, Alfredo De Giorgi, Alessio Di Maria, Laura Maria Scichilone, Matteo Capone, Francesca Maria Vinci, Simone Nicoletti, Marta Bondanelli, Cristina Malaventura, Alda Storari, Domenico Santoro, Sara Dionisi, Fabio Fabbian

Purpose: Social determinants of health have been related with kidney diseases and their outcomes. Financial toxicity (FT) refers to the negative impact of health care costs on clinical conditions. This scoping review aimed to evaluate the literature linking FT with renal diseases.

Patients and methods: We Included all studies analyzing FT and renal disease recorded in PubMed, Embase and Google Scholar between 2013 and 2023. The research question was formulated with reference to the acronym PCC (Problem, Concept and Contest). For each included study, we considered the study design, the population and main results from different populations with distinct renal conditions and the results were summarized in four tables.

Results: Socioeconomic deprivation was the main cause of FT, and the majority of studies on the relationship between FT and chronic kidney disease (CKD) were conducted in the USA (4 studies evaluated the pediatric population and 6 studies included adults). Three studies reported the impact of FT on nephrolithiasis, and 3 studies analyzed the link between FT and renal tumors. The methods used for detecting FT differed and were based on consultations, questionnaires, expenditures and database records analysis. The COmprehensive Score for financial Toxicity (COST) questionnaire was used in 7 studies (43%), and the prevalence of FT was reported to be high in children and adults.

Conclusion: Although the quality of the selected study is limited, due to different populations investigated and heterogeneity in detecting FT, the latter seems to be a frequent finding in people with renal disease. Health care professionals should recognize socioeconomic deprivation as the major cause of FT. Detecting FT could help in prioritizing patient-centered care in populations with renal diseases through the development of strategies aimed at improving care for people with kidney diseases.

目的:健康的社会决定因素与肾脏疾病及其结果有关。经济毒性(FT)是指医疗费用对临床状况的负面影响。本范围综述旨在评估将财务毒性与肾脏疾病相联系的文献:我们纳入了2013年至2023年期间PubMed、Embase和谷歌学术中所有分析FT与肾脏疾病的研究。研究问题的提出参考了缩写词 PCC(问题、概念和竞赛)。对于每项纳入的研究,我们都考虑了研究设计、研究人群以及来自不同肾病人群的主要结果,并将结果汇总在四个表格中:社会经济贫困是导致 FT 的主要原因,有关 FT 与慢性肾脏病(CKD)之间关系的研究大多在美国进行(4 项研究评估了儿童人群,6 项研究纳入了成年人)。3 项研究报告了 FT 对肾炎的影响,3 项研究分析了 FT 与肾肿瘤之间的联系。用于检测 FT 的方法各不相同,分别基于咨询、问卷调查、支出和数据库记录分析。7项研究(43%)使用了经济毒性综合评分(COST)问卷,据报道,儿童和成人的肾结石发病率较高:结论:尽管所选研究的质量有限,但由于调查的人群不同以及在检测财务毒性方面的异质性,后者似乎是肾病患者的一个常见发现。医护人员应认识到,社会经济贫困是导致FT的主要原因。通过制定旨在改善肾脏疾病患者护理的策略,检测 FT 有助于在肾脏疾病患者中优先考虑以患者为中心的护理。
{"title":"Financial Toxicity and Kidney Disease in Children and Adults: A Scoping Review.","authors":"Rossella Siligato, Guido Gembillo, Alfredo De Giorgi, Alessio Di Maria, Laura Maria Scichilone, Matteo Capone, Francesca Maria Vinci, Simone Nicoletti, Marta Bondanelli, Cristina Malaventura, Alda Storari, Domenico Santoro, Sara Dionisi, Fabio Fabbian","doi":"10.2147/IJNRD.S485111","DOIUrl":"10.2147/IJNRD.S485111","url":null,"abstract":"<p><strong>Purpose: </strong>Social determinants of health have been related with kidney diseases and their outcomes. Financial toxicity (FT) refers to the negative impact of health care costs on clinical conditions. This scoping review aimed to evaluate the literature linking FT with renal diseases.</p><p><strong>Patients and methods: </strong>We Included all studies analyzing FT and renal disease recorded in PubMed, Embase and Google Scholar between 2013 and 2023. The research question was formulated with reference to the acronym PCC (Problem, Concept and Contest). For each included study, we considered the study design, the population and main results from different populations with distinct renal conditions and the results were summarized in four tables.</p><p><strong>Results: </strong>Socioeconomic deprivation was the main cause of FT, and the majority of studies on the relationship between FT and chronic kidney disease (CKD) were conducted in the USA (4 studies evaluated the pediatric population and 6 studies included adults). Three studies reported the impact of FT on nephrolithiasis, and 3 studies analyzed the link between FT and renal tumors. The methods used for detecting FT differed and were based on consultations, questionnaires, expenditures and database records analysis. The COmprehensive Score for financial Toxicity (COST) questionnaire was used in 7 studies (43%), and the prevalence of FT was reported to be high in children and adults.</p><p><strong>Conclusion: </strong>Although the quality of the selected study is limited, due to different populations investigated and heterogeneity in detecting FT, the latter seems to be a frequent finding in people with renal disease. Health care professionals should recognize socioeconomic deprivation as the major cause of FT. Detecting FT could help in prioritizing patient-centered care in populations with renal diseases through the development of strategies aimed at improving care for people with kidney diseases.</p>","PeriodicalId":14181,"journal":{"name":"International Journal of Nephrology and Renovascular Disease","volume":"18 ","pages":"13-25"},"PeriodicalIF":2.1,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11770919/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Insights on Childhood Lupus Nephritis. 儿童狼疮性肾炎的新认识。
IF 2.1 Q2 UROLOGY & NEPHROLOGY Pub Date : 2025-01-13 eCollection Date: 2025-01-01 DOI: 10.2147/IJNRD.S405789
Rodrigo Marchi-Silva, Bruna Martins De Aquino, Ana Carolina Londe, Taίs Nitsch Mazzola, Paulo Rogério Julio, Theresa Wampler Muskardin, Simone Appenzeller

Approximately one in five patients with systemic lupus erythematosus (SLE) has disease-onset during childhood (cSLE). Lupus nephritis is more common in cSLE than adult-onset SLE and is associated with significant and increased morbidity and mortality. In this article, we review lupus nephritis in cSLE, including pathogenesis, diagnosis, biomarkers, and management through PUBMED search between July and December 2024. Diagnosis of lupus nephritis is made in 93% of cSLE patients during the first 2 years of disease. The majority of patients have active disease in other organs, and nephrotic range proteinuria and hypertension is frequently observed at diagnosis. Class III and IV are observed in over 50% of renal biopsies and progression to end-stage renal disease varies across cohorts. Major progress made in recent years includes adjustment of the proportion of fibrous crescents when scoring nephritis in cSLE to better discriminate kidney disease outcomes, and development of non-invasive biomarkers to identify renal disease activity and damage. It is anticipated that accurate non-invasive biomarkers will foster multicenter studies and help identify new treatment approaches to improve outcomes in cSLE nephritis.

大约五分之一的系统性红斑狼疮(SLE)患者在儿童期发病(cSLE)。狼疮性肾炎在cSLE中比成人SLE更常见,并且与显著增加的发病率和死亡率相关。在这篇文章中,我们回顾了狼疮性肾炎在cSLE,包括发病机制,诊断,生物标志物,和管理通过PUBMED检索在2024年7月至12月。狼疮性肾炎的诊断在93%的cSLE患者在疾病的头2年。大多数患者在其他器官有活动性疾病,诊断时常观察到肾病范围、蛋白尿和高血压。III类和IV类在超过50%的肾活检中被观察到,并且在不同队列中进展到终末期肾脏疾病有所不同。近年来取得的主要进展包括:调整纤维月牙在评价cSLE肾炎时的比例,以更好地区分肾脏疾病的预后,以及开发非侵入性生物标志物来识别肾脏疾病的活动性和损害。预计准确的非侵入性生物标志物将促进多中心研究,并帮助确定新的治疗方法来改善cSLE肾炎的预后。
{"title":"New Insights on Childhood Lupus Nephritis.","authors":"Rodrigo Marchi-Silva, Bruna Martins De Aquino, Ana Carolina Londe, Taίs Nitsch Mazzola, Paulo Rogério Julio, Theresa Wampler Muskardin, Simone Appenzeller","doi":"10.2147/IJNRD.S405789","DOIUrl":"10.2147/IJNRD.S405789","url":null,"abstract":"<p><p>Approximately one in five patients with systemic lupus erythematosus (SLE) has disease-onset during childhood (cSLE). Lupus nephritis is more common in cSLE than adult-onset SLE and is associated with significant and increased morbidity and mortality. In this article, we review lupus nephritis in cSLE, including pathogenesis, diagnosis, biomarkers, and management through PUBMED search between July and December 2024. Diagnosis of lupus nephritis is made in 93% of cSLE patients during the first 2 years of disease. The majority of patients have active disease in other organs, and nephrotic range proteinuria and hypertension is frequently observed at diagnosis. Class III and IV are observed in over 50% of renal biopsies and progression to end-stage renal disease varies across cohorts. Major progress made in recent years includes adjustment of the proportion of fibrous crescents when scoring nephritis in cSLE to better discriminate kidney disease outcomes, and development of non-invasive biomarkers to identify renal disease activity and damage. It is anticipated that accurate non-invasive biomarkers will foster multicenter studies and help identify new treatment approaches to improve outcomes in cSLE nephritis.</p>","PeriodicalId":14181,"journal":{"name":"International Journal of Nephrology and Renovascular Disease","volume":"18 ","pages":"1-12"},"PeriodicalIF":2.1,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11740589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification and Management of CKD-Associated Pruritus: Current Insights. ckd相关瘙痒的识别和管理:当前的见解。
IF 2.1 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-12-28 eCollection Date: 2024-01-01 DOI: 10.2147/IJNRD.S499798
Tomasz Skrzypczak, Anna Skrzypczak, Piotr Nockowski, Jacek C Szepietowski

Chronic kidney disease-associated pruritus (CKD-aP) is a frequent and distressing problem for individuals with chronic kidney disease (CKD) and end-stage renal disease. It affects around 20% of those with CKD and 40% of those with end-stage renal disease. Despite its clear association with poorer psychosocial and medical outcomes, it is often underreported by patients and frequently remains unnoticed by healthcare providers. This is likely due to uncertainty regarding its diagnosis and treatment. Most commonly, CKD-aP could be screened with questionnaires like the KDQoL-36 and WI-NRS, chosen for their simplicity and ease of use. Prior treatment studies of CKD-aP were mostly limited by noncontrolled design and small sample size. First CKD-aP medication - difelikefalin a powerful, new therapeutic option was approved by Federal Drug Administration (FDA) in 2021 and European Medicines Agency (EMA) in 2022. Recent expert opinions, clinical trials and metanalysis identified difelikefalin and gabapentinoids as medications of choice in treatment of CKD-aP. All these findings improved current understanding and management of this condition.

慢性肾脏疾病相关性瘙痒(CKD- ap)是慢性肾脏疾病(CKD)和终末期肾脏疾病患者的常见和令人痛苦的问题。它影响了大约20%的CKD患者和40%的终末期肾病患者。尽管它与较差的社会心理和医疗结果明显相关,但它往往被患者低估,并且经常被医疗保健提供者忽视。这可能是由于其诊断和治疗的不确定性。最常见的是,CKD-aP可以通过像KDQoL-36和WI-NRS这样的问卷进行筛查,选择这些问卷是因为它们简单易用。先前CKD-aP的治疗研究大多受到非对照设计和小样本量的限制。首个CKD-aP药物- difelikefalin是一种强大的新治疗选择,于2021年获得美国联邦药物管理局(FDA)批准,并于2022年获得欧洲药品管理局(EMA)批准。最近的专家意见、临床试验和荟萃分析确定异花铁素和加巴喷丁类药物是治疗CKD-aP的首选药物。所有这些发现都改善了目前对这种疾病的理解和管理。
{"title":"Identification and Management of CKD-Associated Pruritus: Current Insights.","authors":"Tomasz Skrzypczak, Anna Skrzypczak, Piotr Nockowski, Jacek C Szepietowski","doi":"10.2147/IJNRD.S499798","DOIUrl":"10.2147/IJNRD.S499798","url":null,"abstract":"<p><p>Chronic kidney disease-associated pruritus (CKD-aP) is a frequent and distressing problem for individuals with chronic kidney disease (CKD) and end-stage renal disease. It affects around 20% of those with CKD and 40% of those with end-stage renal disease. Despite its clear association with poorer psychosocial and medical outcomes, it is often underreported by patients and frequently remains unnoticed by healthcare providers. This is likely due to uncertainty regarding its diagnosis and treatment. Most commonly, CKD-aP could be screened with questionnaires like the KDQoL-36 and WI-NRS, chosen for their simplicity and ease of use. Prior treatment studies of CKD-aP were mostly limited by noncontrolled design and small sample size. First CKD-aP medication - difelikefalin a powerful, new therapeutic option was approved by Federal Drug Administration (FDA) in 2021 and European Medicines Agency (EMA) in 2022. Recent expert opinions, clinical trials and metanalysis identified difelikefalin and gabapentinoids as medications of choice in treatment of CKD-aP. All these findings improved current understanding and management of this condition.</p>","PeriodicalId":14181,"journal":{"name":"International Journal of Nephrology and Renovascular Disease","volume":"17 ","pages":"339-354"},"PeriodicalIF":2.1,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11693948/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pediatric Acute Lobar Nephronia: A Case Series and Literature Review. 儿童急性大叶性肾病:病例系列及文献回顾。
IF 2.1 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-12-17 eCollection Date: 2024-01-01 DOI: 10.2147/IJNRD.S491182
Kfir Lavi, Adi Klein, Noy Shtein, Vered Schichter Konfino, Vered Nir

Introduction: Acute lobar nephronia (ALN) is a focal renal infection without liquefaction, historically regarded as rare in the pediatric population, yet recent literature suggests it may be under-diagnosed, which may result in the formation of renal abscess and future renal scarring.

Methods: The clinical presentation, investigations, treatment and long-term outcomes of 5 patients diagnosed with ALN was described and literature review was conducted by reviewing publications in PubMed using the keywords "acute lobar nephronia" and "pediatric".

Results: Three patients were males, aged 1 to 11 years. The primary complaint in all cases was fever, accompanied by significantly elevated inflammatory markers. Upon presentation, none of the patients exhibited pyuria on urinalysis, and all had sterile blood and urine cultures. Diagnosis was based on CT scans for three patients and renal sonography for two. Main findings included hyperechogenic renal parenchyma, and hypodense localized parenchyma. Treatment consisted of broad-spectrum intravenous antibiotics, administered for 7 to 12 days and additional 1 week course with amoxicillin-clavulanate, resulting in similar defervescence times across all patients. None of the patients demonstrated recurrence and none had renal pathology upon repeated renal sonography and upon DMSA scintigraphy.

Discussion: Clinical suspicion for ALN should arise in cases of abdominal pain and markedly increased inflammatory markers. It"s crucial to note that the absence of pyuria and negative culture results should not exclude ALN diagnosis, underscoring the need for a high index of suspicion in the pediatric population.

简介:急性大叶性肾病(ALN)是一种没有液化的局灶性肾脏感染,历来被认为在儿科人群中罕见,但最近的文献表明,它可能被诊断不足,这可能导致肾脓肿的形成和未来的肾瘢痕。方法:以“急性大叶性肾病”和“儿科”为关键词,对5例ALN患者的临床表现、调查、治疗及远期预后进行分析,并对PubMed上发表的文献进行复习。结果:男性3例,年龄1 ~ 11岁。所有病例的主要主诉均为发热,并伴有炎症标志物显著升高。在就诊时,没有患者在尿液分析中表现出脓尿,所有患者都有无菌血和尿培养。三名患者的诊断是基于CT扫描,两名患者的肾脏超声检查。主要表现为肾实质高回声,局限性实质低密度。治疗包括广谱静脉注射抗生素,给药7 - 12天,另外用阿莫西林-克拉维酸治疗1周,所有患者的退热时间相似。经反复肾超声检查和DMSA显像检查均无复发,无肾脏病变。讨论:在腹痛和炎症标志物明显增加的情况下,临床应怀疑ALN。重要的是要注意,没有脓尿和阴性培养结果不应排除ALN的诊断,强调在儿科人群中需要高度怀疑。
{"title":"Pediatric Acute Lobar Nephronia: A Case Series and Literature Review.","authors":"Kfir Lavi, Adi Klein, Noy Shtein, Vered Schichter Konfino, Vered Nir","doi":"10.2147/IJNRD.S491182","DOIUrl":"10.2147/IJNRD.S491182","url":null,"abstract":"<p><strong>Introduction: </strong>Acute lobar nephronia (ALN) is a focal renal infection without liquefaction, historically regarded as rare in the pediatric population, yet recent literature suggests it may be under-diagnosed, which may result in the formation of renal abscess and future renal scarring.</p><p><strong>Methods: </strong>The clinical presentation, investigations, treatment and long-term outcomes of 5 patients diagnosed with ALN was described and literature review was conducted by reviewing publications in PubMed using the keywords \"acute lobar nephronia\" and \"pediatric\".</p><p><strong>Results: </strong>Three patients were males, aged 1 to 11 years. The primary complaint in all cases was fever, accompanied by significantly elevated inflammatory markers. Upon presentation, none of the patients exhibited pyuria on urinalysis, and all had sterile blood and urine cultures. Diagnosis was based on CT scans for three patients and renal sonography for two. Main findings included hyperechogenic renal parenchyma, and hypodense localized parenchyma. Treatment consisted of broad-spectrum intravenous antibiotics, administered for 7 to 12 days and additional 1 week course with amoxicillin-clavulanate, resulting in similar defervescence times across all patients. None of the patients demonstrated recurrence and none had renal pathology upon repeated renal sonography and upon DMSA scintigraphy.</p><p><strong>Discussion: </strong>Clinical suspicion for ALN should arise in cases of abdominal pain and markedly increased inflammatory markers. It\"s crucial to note that the absence of pyuria and negative culture results should not exclude ALN diagnosis, underscoring the need for a high index of suspicion in the pediatric population.</p>","PeriodicalId":14181,"journal":{"name":"International Journal of Nephrology and Renovascular Disease","volume":"17 ","pages":"333-337"},"PeriodicalIF":2.1,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11662641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Nephrology and Renovascular Disease
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1